Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Immunovia

BATS-CHIXE:IMMNOS
Snowflake Description

Flawless balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
IMMNOS
BATS-CHIXE
SEK3B
Market Cap
  1. Home
  2. GB
  3. Healthcare
Company description

Immunovia AB (publ), a molecular diagnostics company, develops and commercializes diagnostic tools for cancer and autoimmune diseases in Sweden and internationally. The last earnings update was 18 days ago. More info.


Add to Portfolio Compare Print
  • Immunovia has significant price volatility in the past 3 months.
IMMNOS Share Price and Events
7 Day Returns
1.3%
BATS-CHIXE:IMMNOS
-1.2%
GB Medical Equipment
0.1%
GB Market
1 Year Returns
-
BATS-CHIXE:IMMNOS
-0.3%
GB Medical Equipment
-23.6%
GB Market
IMMNOS Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Immunovia (IMMNOS) 1.3% -17.5% -26.9% - - -
GB Medical Equipment -1.2% -12% -19.1% -0.3% -2.3% 20.9%
GB Market 0.1% -15.5% -27% -23.6% -24.3% -23.5%
1 Year Return vs Industry and Market
  • No trading data on IMMNOS.
  • No trading data on IMMNOS.
Price Volatility
IMMNOS
Industry
5yr Volatility vs Market
Related Companies

IMMNOS Value

 Is Immunovia undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Immunovia. This is due to cash flow or dividend data being unavailable. The share price is SEK120.4.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Immunovia's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Immunovia's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BATS-CHIXE:IMMNOS PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in SEK SEK-5.85
OM:IMMNOV Share Price ** OM (2020-04-03) in SEK SEK128
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PE Ratio Median Figure of 11 Publicly-Listed Medical Equipment Companies 25.55x
United Kingdom of Great Britain and Northern Ireland Market PE Ratio Median Figure of 748 Publicly-Listed Companies 12.61x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Immunovia.

BATS-CHIXE:IMMNOS PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OM:IMMNOV Share Price ÷ EPS (both in SEK)

= 128 ÷ -5.85

-21.87x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Immunovia is loss making, we can't compare its value to the GB Medical Equipment industry average.
  • Immunovia is loss making, we can't compare the value of its earnings to the United Kingdom of Great Britain and Northern Ireland market.
Price based on expected Growth
Does Immunovia's expected growth come at a high price?
Raw Data
BATS-CHIXE:IMMNOS PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -21.87x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PEG Ratio Median Figure of 8 Publicly-Listed Medical Equipment Companies 2x
United Kingdom of Great Britain and Northern Ireland Market PEG Ratio Median Figure of 517 Publicly-Listed Companies 0.99x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Immunovia, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Immunovia's assets?
Raw Data
BATS-CHIXE:IMMNOS PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in SEK SEK18.19
OM:IMMNOV Share Price * OM (2020-04-03) in SEK SEK128
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PB Ratio Median Figure of 20 Publicly-Listed Medical Equipment Companies 2.83x
United Kingdom of Great Britain and Northern Ireland Market PB Ratio Median Figure of 1,323 Publicly-Listed Companies 1.11x
BATS-CHIXE:IMMNOS PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OM:IMMNOV Share Price ÷ Book Value per Share (both in SEK)

= 128 ÷ 18.19

7.04x

* Primary Listing of Immunovia.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Immunovia is overvalued based on assets compared to the GB Medical Equipment industry average.
X
Value checks
We assess Immunovia's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Immunovia has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

IMMNOS Future Performance

 How is Immunovia expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Immunovia has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
21.1%
Expected Medical Equipment industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Immunovia expected to grow at an attractive rate?
  • Unable to compare Immunovia's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Immunovia's earnings growth to the United Kingdom of Great Britain and Northern Ireland market average as no estimate data is available.
  • Unable to compare Immunovia's revenue growth to the United Kingdom of Great Britain and Northern Ireland market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
BATS-CHIXE:IMMNOS Future Growth Rates Data Sources
Data Point Source Value (per year)
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 21.1%
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 6.2%
United Kingdom of Great Britain and Northern Ireland Market Earnings Growth Rate Market Cap Weighted Average 15.5%
United Kingdom of Great Britain and Northern Ireland Market Revenue Growth Rate Market Cap Weighted Average 2.5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BATS-CHIXE:IMMNOS Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in SEK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BATS-CHIXE:IMMNOS Future Estimates Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
BATS-CHIXE:IMMNOS Past Financials Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income *
2019-12-31 0 -92 -115
2019-09-30 24 -95 -108
2019-06-30 24 -89 -99
2019-03-31 25 -83 -96
2018-12-31 0 -84 -87
2018-09-30 29 -75 -76
2018-06-30 26 -63 -70
2018-03-31 25 -55 -55
2017-12-31 24 -46 -45
2017-09-30 23 -36 -35
2017-06-30 24 -25 -28
2017-03-31 25 -11 -20

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Immunovia is high growth as no earnings estimate data is available.
  • Unable to determine if Immunovia is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BATS-CHIXE:IMMNOS Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Immunovia Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:IMMNOS Future Estimates Data
Date (Data in SEK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
BATS-CHIXE:IMMNOS Past Financials Data
Date (Data in SEK Millions) EPS *
2019-12-31 -5.85
2019-09-30 -5.50
2019-06-30 -5.09
2019-03-31 -5.01
2018-12-31 -4.67
2018-09-30 -4.24
2018-06-30 -4.06
2018-03-31 -3.21
2017-12-31 -2.67
2017-09-30 -2.10
2017-06-30 -1.71
2017-03-31 -1.29

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Immunovia will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Immunovia's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Immunovia's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Immunovia's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Immunovia has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

IMMNOS Past Performance

  How has Immunovia performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Immunovia's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Immunovia does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Immunovia's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Immunovia's 1-year growth to the GB Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
Immunovia's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Immunovia Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:IMMNOS Past Revenue, Cash Flow and Net Income Data
Date (Data in SEK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 0.36 -114.52 54.58
2019-09-30 24.22 -107.56 55.59
2019-06-30 24.50 -99.34 54.58
2019-03-31 25.07 -95.60 51.92
2018-12-31 0.33 -86.54 45.26
2018-09-30 28.58 -76.20 45.81
2018-06-30 26.26 -70.39 38.05
2018-03-31 24.96 -54.79 33.59
2017-12-31 24.19 -45.23 30.64
2017-09-30 23.05 -35.29 23.83
2017-06-30 23.72 -27.75 23.13
2017-03-31 24.86 -20.09 18.61
2016-12-31 24.50 -14.72 15.71
2016-09-30 22.14 -11.13 11.53
2016-06-30 21.98 -8.87 10.92
2016-03-31 18.70 -7.89 9.05
2015-12-31 17.00 -7.38 7.27
2015-09-30 12.11 -8.61 5.50
2015-06-30 7.22 -9.83 3.72
2015-03-31 3.79 -9.34 2.68
2014-12-31 0.36 -8.86 1.65
2013-12-31 1.18 -1.60 0.59

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Immunovia has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Immunovia has efficiently used its assets last year compared to the GB Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Immunovia improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Immunovia's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Immunovia has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

IMMNOS Health

 How is Immunovia's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Immunovia's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Immunovia is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Immunovia's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Immunovia's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Immunovia has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Immunovia Company Filings, last reported 3 months ago.

BATS-CHIXE:IMMNOS Past Debt and Equity Data
Date (Data in SEK Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 357.60 0.00 263.35
2019-09-30 388.01 0.00 297.22
2019-06-30 405.03 0.00 327.46
2019-03-31 434.83 0.00 359.85
2018-12-31 461.95 0.00 386.14
2018-09-30 487.75 0.00 415.60
2018-06-30 503.34 0.00 447.21
2018-03-31 219.37 0.00 167.79
2017-12-31 236.80 0.00 192.43
2017-09-30 252.11 0.00 215.30
2017-06-30 258.78 0.00 228.33
2017-03-31 268.86 0.00 246.36
2016-12-31 276.63 0.00 259.09
2016-09-30
2016-06-30 78.70 0.00 59.73
2016-03-31 83.80 0.00 75.77
2015-12-31 83.80 0.00 75.77
2015-09-30 83.80 0.00 75.77
2015-06-30 31.98 0.00 22.76
2015-03-31 31.98 0.00 22.76
2014-12-31 35.74 0.00 31.80
2013-12-31 4.94 0.00 3.61
  • Immunovia has no debt.
  • Immunovia has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Immunovia has sufficient cash runway for 2 years based on current free cash flow.
  • Immunovia has sufficient cash runway for 2.6 years if free cash flow continues to grow at historical rates of 40.8% each year.
X
Financial health checks
We assess Immunovia's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Immunovia has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

IMMNOS Dividends

 What is Immunovia's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Immunovia dividends.
If you bought SEK2,000 of Immunovia shares you are expected to receive SEK0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Immunovia's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Immunovia's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BATS-CHIXE:IMMNOS Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 2.2%
United Kingdom of Great Britain and Northern Ireland Market Average Dividend Yield Market Cap Weighted Average of 588 Stocks 5.6%
United Kingdom of Great Britain and Northern Ireland Minimum Threshold Dividend Yield 10th Percentile 1.3%
United Kingdom of Great Britain and Northern Ireland Bottom 25% Dividend Yield 25th Percentile 2.6%
United Kingdom of Great Britain and Northern Ireland Top 25% Dividend Yield 75th Percentile 7.1%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BATS-CHIXE:IMMNOS Future Dividends Estimate Data
Date (Data in SEK) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Immunovia has not reported any payouts.
  • Unable to verify if Immunovia's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Immunovia's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Immunovia has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Immunovia's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Immunovia afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Immunovia has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

IMMNOS Management

 What is the CEO of Immunovia's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mats Grahn
COMPENSATION SEK3,680,000
AGE 57
TENURE AS CEO 7.3 years
CEO Bio

Mr. Mats Grahn has been Chief Executive Officer of Immunovia AB (publ) since 2013. Mr. Grahn served as the Vice President of Product Management of Protein Separations at GE Healthcare Ltd. He has more than 25 years experiences in senior leading positions within the life science and diagnostics industry. He has an extensive experience in business and strategic development, marketing, product management, product development and market access. He has a track record of leading international commercial operational organizations, restructuring of marketing organizations, integration of acquired companies as well as managing new start-ups. He served as a Corporate Vice President of Marketing at Dako Denmark A/S since June 1, 2007. He served as Vice President of Product Marketing at Dako A/S from 2006 to 2007, Vice President of Product Management, Proteomics of Amersham Pharmacia Biotech, Discovery Systems from 2002 to 2003, Vice President of Product Management of protein separations of GE Healthcare from 2003 to 2006, Vice President of Prevas bioinformatics of Prevas AB from 2000 to 2001, Senior Project Manager of Research & Development at Pharmacia Biotech from 1989 to 1996 and Automation Engineer of ASEA BROWN BOVERI from 1987 to 1989. Mr. Grahn served as Vice President of Laboratory Separations from 1998 to 2000 and Director of Engineering Division for Amersham Pharmacia Biotech from 1996 to 1998. He served as Chairman and Director of Alligator Bioscience AB since December 2009 and 2006 respectively. Mr. Grahn holds an MSc in Engineering Physics from Lund University in 1986.

CEO Compensation
  • Mats's compensation has increased whilst company is loss making.
  • Mats's remuneration is lower than average for companies of similar size in United Kingdom of Great Britain and Northern Ireland.
Management Team Tenure

Average tenure and age of the Immunovia management team in years:

5.3
Average Tenure
57
Average Age
  • The average tenure for the Immunovia management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Mats Grahn

TITLE
Chief Executive Officer
COMPENSATION
SEK4M
AGE
57
TENURE
7.3 yrs

Hans Liljenborg

TITLE
Chief Financial Officer
AGE
61
TENURE
7.3 yrs

Lotta Blomgren

TITLE
Operations Director
AGE
59
TENURE
3.6 yrs

Peter Schulz-Knappe

TITLE
Chief Technology Officer
TENURE
0.3 yrs

Rolf Ehrnström

TITLE
Chief Scientific Officer
AGE
66
TENURE
7.3 yrs

Julie Silber

TITLE
Director of Investor Relations

Laura Chirica

TITLE
Chief Commercial Officer
AGE
51
TENURE
5.3 yrs

Henrik Winther

TITLE
Senior Vice President of Business Development
AGE
53
TENURE
2.9 yrs

Mike Pettigrew

TITLE
Senior Vice President of Sales - North America
TENURE
0.3 yrs

Linda Mellby

TITLE
Vice President of Research & Development
AGE
40
TENURE
6.3 yrs
Board of Directors Tenure

Average tenure and age of the Immunovia board of directors in years:

3.5
Average Tenure
60
Average Age
  • The tenure for the Immunovia board of directors is about average.
Board of Directors

Carl Arne Borrebäck

TITLE
Chairman of the Board of Directors
COMPENSATION
SEK420K
AGE
71
TENURE
13.3 yrs

Ann-Christine Sundell

TITLE
Director
COMPENSATION
SEK190K
AGE
55
TENURE
3.3 yrs

Christofer Sjögren

TITLE
Director
COMPENSATION
SEK177K
AGE
53
TENURE
2.3 yrs

Marco Del Chiaro

TITLE
Member of Advisory Board
TENURE
4 yrs

Margaret Tempero

TITLE
Member of Scientific Advisory Board
TENURE
3.8 yrs

Aldo Scarpa

TITLE
Member of Scientific Advisory Board
TENURE
3.8 yrs

Diane Simeone

TITLE
Member of Scientific Advisory Board
TENURE
3.8 yrs

Hans Johansson

TITLE
Director
COMPENSATION
SEK170K
AGE
65
TENURE
3.3 yrs

Stephen Pereira

TITLE
Member of Scientific Advisory Board
TENURE
2.8 yrs

Mimmi Ekberg

TITLE
Director
COMPENSATION
SEK150K
AGE
60
TENURE
2.3 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Immunovia individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (SEK) Value (SEK)
24. Mar 20 Buy Hans Johansson Individual 24. Mar 20 24. Mar 20 5,082 SEK98.47 SEK500,425
X
Management checks
We assess Immunovia's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Immunovia has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

IMMNOS News

Simply Wall St News

IMMNOS Company Info

Description

Immunovia AB (publ), a molecular diagnostics company, develops and commercializes diagnostic tools for cancer and autoimmune diseases in Sweden and internationally. The company offers IMMray PanCan-d, a blood-based test for the detection of pancreatic cancer. Immunovia AB (publ) was founded in 2007 and is headquartered in Lund, Sweden.

Details
Name: Immunovia AB (publ)
IMMNOS
Exchange: BATS-CHIXE
Founded: 2007
SEK2,555,130,890
19,654,853
Website: http://www.immunovia.com
Address: Immunovia AB (publ)
Medicon Village,
Scheelevägen 2,
Lund,
Skåne County, 223 81,
Sweden
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OM IMMNOV Share Capital OMX Nordic Exchange Stockholm SE SEK 01. Dec 2015
OTCPK IMMV.F Share Capital Pink Sheets LLC US USD 01. Dec 2015
LSE 0G8X Share Capital London Stock Exchange GB SEK 01. Dec 2015
BATS-CHIXE IMMNOS Share Capital BATS 'Chi-X Europe' GB SEK 01. Dec 2015
Number of employees
Current staff
Staff numbers
49
Immunovia employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/07 19:52
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2019/03/04
Last earnings filing: 2020/03/20
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.